Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
July 11 2023 - 6:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of July 2023
001-40614
(Commission
File Number)
INTERCURE
LTD.
(Exact
name of Registrant as specified in its charter)
85
Medinat ha-Yehudim Street
Herzliya,
4676670, Israel
Tel:
+972 77 460 5012
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Intercure
Ltd. |
|
|
|
Date:
July 11, 2023 |
By: |
/s/
Amos Cohen |
|
|
Amos
Cohen
Chief
Financial Officer |
Exhibit
99.1
InterCure
Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE
NEW
YORK, TORONTO, and HERZLIYA, Israel — July 10, 2023 — InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR)
(dba Canndoc)(“InterCure” or the “Company”), announced today that its board of directors (“Board”)
has approved the voluntarily delisting of the Company’s common shares (“Shares”) from the Toronto Stock Exchange
(the “TSX”) (the “Delisting”).
The
Company has decided to delist from the TSX after concluding that maintaining the listing does not offer substantial benefits to the Company
and its shareholders. The Shares are currently listed on the NASDAQ and the Tel Aviv Stock Exchange, in addition to them being listed
on the TSX. After a careful review of the trading volume data relating to the Shares, the Board has concluded that the trading volume
on the TSX in insufficient to justify the continued listing.
The
Issuer will, however, remain a “reporting issuer” under applicable Canadian securities laws and continue to provide regular
comprehensive disclosure pursuant to National Instrument 71-102 – Continues Disclosure and Other Exemptions Relating to Foreign
Issuers as a “SEC Foreign Issuer”.
Most
brokers in Canada, including discount and online brokers, have the ability to buy and sell securities listed on the NASDAQ. Therefore,
the Company’s NASDAQ listing will continue to provide shareholders with the same accessibility to trade the Company’s common
shares. The value of the Company’s common shares is not related to or dependent on the TSX listing. Shareholders holding common
shares in Canadian brokerage accounts should contact their brokers to confirm how to trade the Company’s shares on the NASDAQ.
The
Company has applied to the TSX to delist the Shares from the TSX at the end of the trading session on August 14, 2023. The Delisting
is subject to the approval of the TSX. As per Section 720 of the TSX Company Manual, shareholder approval is not required as an acceptable
alternate market exists for the listed securities. In connection with the Delisting, in accordance with Israeli securities laws, the
Company will seek the approval of its shareholders, at a special meeting of shareholders called on August 14, 2023, to rely on the dual
listing of the Shares on the Nasdaq Global Market and on Tel Aviv Stock Exchange for the purposes of compliance with Israeli securities
laws, in accordance with Section 35FF of the Israeli Securities Law, 5728-1968.
About
InterCure (dba Canndoc)
InterCure
(dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North
America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to
offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market
leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale”
model to lead the fastest growing cannabis global market outside of North America.
For
more information, visit: http://www.intercure.co.
Forward-Looking
Statements
This
press release may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating
to the Delisting, as well as statements, other than historical facts, that address activities, events or developments that InterCure
intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology
such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience
and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate..
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure’s actual activities
or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited
to, the failure to obtain the required approval of the TSX for the Delisting. InterCure undertakes no obligation to update such forward-looking
information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Contact:
InterCure
Ltd.
Amos
Cohen, Chief Financial Officer
amos@intercure.co
Intercure (NASDAQ:INCR)
Historical Stock Chart
From May 2024 to Jun 2024
Intercure (NASDAQ:INCR)
Historical Stock Chart
From Jun 2023 to Jun 2024